Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

General Pain

COVID-19 Vaccine Candidate More Than 90% Effective

Diana Ernst, RPh

November 12, 2020

The mRNA-based vaccine candidate, BNT162b2, has been shown to be more than 90% effective in preventing COVID-19.

General Pain

ACIP: Influenza Vaccination Recommendations for 2020-2021

Diana Ernst, RPh

August 27, 2020

Influenza vaccination should occur by the end of October, if possible.

General Pain

Study to Assess Antiviral Antibody Cocktail for COVID-19 Prevention Begins

Diana Ernst, RPh

July 10, 2020

A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.

General Pain

Warning Letters Issued to Companies Selling Unapproved “Homeopathic” Injectables

Diana Ernst, RPh

June 23, 2020

The FDA has issued warning letters to several companies selling unapproved injectable products labeled as homeopathic.

Migraine & Headache

Oral Formulation of Celecoxib Approved for Acute Migraine

Diana Ernst, RPh

May 12, 2020

The FDA has approved Elyxyb an oral solution formulation of celecoxib, for the acute treatment of migraine with or without aura in adults.

Musculoskeletal Pain

Duloxetine Now Approved for Pediatric Fibromyalgia

Diana Ernst, RPh

April 23, 2020

The Food and Drug Administration (FDA) has expanded the approval of Cymbalta to include treatment of fibromyalgia in pediatric patients 13 to 17 years of age.

General Pain

Drug Shortages Reported as New Program Created to Expedite Treatments for COVID-19

Diana Ernst, RPh

April 2, 2020

To expedite development, the FDA has created a special emergency program called the Coronavirus Treatment Acceleration Program.

Practice Management

Update on REMS-Required Testing During COVID-19 Pandemic

Diana Ernst, RPh

March 23, 2020

For patients suspected of having COVID-19, undergoing REMS-required testing to obtain a medication may put others at risk.

Acute Pain

FDA Approves Meloxicam Injection for Moderate to Severe Pain

Diana Ernst, RPh

February 25, 2020

The FDA has approved Anjeso (meloxicam injection; Baudax Bio) for the management of moderate to severe pain, alone or in combination with NSAIDs in adult patients.

Acute Pain

FDA Approves OTC Switch of Diclofenac Topical Gel

Diana Ernst, RPh

February 20, 2020

Diclofenac sodium topical gel and olopatadine HCl ophthalmic drops will soon be available over-the-counter (OTC) after the the Food and Drug Administration (FDA) switched the status of these products from prescription to nonprescription.

Next post in Acute Pain